Provided by Tiger Trade Technology Pte. Ltd.

Novo-Nordisk A/S

47.64
+4.309.92%
Pre-market: 50.943.30+6.93%06:08 EST
Volume:36.86M
Turnover:1.72B
Market Cap:211.48B
PE:13.16
High:47.74
Open:46.37
Low:45.84
Close:43.34
52wk High:93.80
52wk Low:43.08
Shares:4.44B
Float Shares:3.19B
Volume Ratio:0.92
T/O Rate:1.16%
Dividend:1.72
Dividend Rate:3.61%
EPS(TTM):3.62
EPS(LYR):3.62
ROE:60.70%
ROA:17.43%
PB:7.40
PE(LYR):13.16

Loading ...

Novo Nordisk Shares Rise As Hims Abandons $49 Weight-Loss Pill

Reuters
·
2 hours ago

Hims & Hers Stock Plunges 15%. Why Losing the Novo Wegovy Battle Is a Blow. -- Barrons.com

Dow Jones
·
59 mins ago

Barclays Remains a Hold on Novo Nordisk (0QIU)

TIPRANKS
·
1 hour ago

HIMS Stock Drops, NVO Jumps after Hims & Hers Halts Selling $49 Wegovy Copy

TIPRANKS
·
1 hour ago

Premarket Movers | Space Stocks Rally With Virgin Galactic up over 8%; AI Application Software Shares Gain With AppLovin up over 5%, Palantir up over 2%

Tiger Newspress
·
1 hour ago

Stock Track | Novo Nordisk Soars 6.63% in Pre-Market as Hims & Hers Halts Competitive Weight-Loss Pill

Stock Track
·
2 hours ago

Hims & Hers stock poised for heavy losses after quick U-turn on plan for oral Wegovy competitor

Dow Jones
·
2 hours ago

Novo Nordisk Faces Price War in Competitive Anti-Obesity Drug Market with No Relief in Sight

Deep News
·
3 hours ago

24H | Big Techs Mostly Jump With Palantir, Oracle up Around 2%; Chip Shares Gain With Marvell, SOXL, SanDisk up over 2%; Novo Rallies 5%

Tiger Newspress
·
9 hours ago

Stock Track | Novo Nordisk Soars 6.44% in Overnight Trading After FDA Action Against Rival's Wegovy Copy

Stock Track
·
9 hours ago

Gartner, Stellantis, And Novo Nordisk Are Among Top 10 Large Cap Losers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio?

Benzinga
·
Yesterday

Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny -- Barrons.com

Dow Jones
·
Yesterday

The Weight-Loss Price Wars Are Breaking Big Pharma's Business Model -- Heard on the Street -- WSJ

Dow Jones
·
Feb 07

Review -- Barron's

Dow Jones
·
Feb 07

Health Care Up as Novo Nordisk Recoups Some Losses -- Health Care Roundup

Dow Jones
·
Feb 07

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Feb 07

FDA Vows Swift Action Against Unapproved Drugs, Derailing HIMS' Weight-Loss Copycat Plan; Shares Drop Nearly 6%

Deep News
·
Feb 07

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
Feb 07

European Markets Gain Amid Volatility as Novo Nordisk Rebound Offsets Stellantis Plunge

Deep News
·
Feb 07

Novo Nordisk A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Feb 07